ArticleClinical and molecular hepatology2020
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients.
Article in Clinical and molecular hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Comparative effectiveness of several adjuvant therapies for patients with hepatocellular carcinoma with high-risk factors for recurrence after hepatectomy: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Outcomes of early-stage hepatocellular carcinoma patients treated by resection or ablation: real-life data from the French Administrative Health Care database.Journal of liver cancer · 2026Article
- Review
- Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab Plus Tremelimumab): A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Beyond VEGF: AEG-1/MTDH as a Systems-Level Orchestrator of Angiogenesis in Hepatocellular Carcinoma.Cells · 2026Review
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Prognostic value of combined FIB-4 and AFP in predicting survival after hepatectomy for hepatocellular carcinoma: a multicenter cohort study.BMC cancer · 2026Article
- Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world study.The oncologist · 2026Article
- Deciphering the role of SIRT6 in suppressing the AMPK-mTOR-TFEB axis: regulation of autophagy activation in HCC.Cancer gene therapy · 2026Article
- Correspondence to editorial on "Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography".Clinical and molecular hepatology · 2026Article
- Imperatorin: A Furanocoumarin with Potential in Combating Cancer Development and Progression-A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Survival Advantage of Prior Curative Hepatectomy in Patients with Hepatocellular Carcinoma Receiving First-Line Multikinase Inhibitors: A Propensity Score-Adjusted Study.Journal of hepatocellular carcinoma · 2026Article
- High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients.Journal of hepatocellular carcinoma · 2026Article
- Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma.Cancers · 2025Review
- Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference.International journal of clinical oncology · 2025Review
- Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencing.JHEP reports : innovation in hepatology · 2025Article
- Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography.Clinical and molecular hepatology · 2025Observational
- Machine Learning-Based Model for Predicting Recurrence-Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients.Cancer medicine · 2025Article
- Predictors of long-term survival outcomes of patients with hepatocellular carcinoma without recurrence at five years after liver resection.Langenbeck's archives of surgery · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsAlthough hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience recurrence for more than 5 years after resection or radiofrequency ablation for early-stage HCC. For those with five recurrence-free period, the risk of HCC recurrence within the next 5 years remains unknown.
methodsA total of 1,451 consecutive patients (median, 55 years old; males, 79.0%; hepatitis B virus-related, 79.3%) with good liver function (Child-Pugh class A) diagnosed with early-stage HCC by Barcelona Clinic Liver Cancer Staging and received radiofrequency ablation or resection as an initial treatment between 2005 and 2010 were analyzed.
resultsDuring a median follow-up period of 8.1 years, 961 patients (66.2%) experienced HCC recurrence. The cumulative recurrence rates increased to 39.7%, 60.3%, and 71.0% at 2, 5, and 10 years, respectively, and did not reach a plateau. Five years after HCC diagnosis, 487 patients were alive without experiencing a recurrence. Among them, during a median of 3.9 additional years of follow-up (range, 0.1-9.0 years), 127 patients (26.1%) experienced recurrence. The next 5-year cumulative recurrence rate (5-10 years from initial diagnosis) was 27.0%. Male sex, higher fibrosis-4 scores, and alpha-fetoprotein levels at 5 years were associated with later HCC recurrence among patients who did not experience recurrence for more than 5 years.
conclusionThe HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.